Experimental Hematology & Oncology

Article	Citations
Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome	136
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	135
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	120
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	110
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	103
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	97
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	79
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	71
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	61
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	59
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	59
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	58
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	54
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	53
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	52
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	51
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	51
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	50
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	48
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	48
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	47
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	47
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas	43
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	42
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	42

Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	41
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	40
Breast cancer heterogeneity and its implication in personalized precision therapy	39
Role of m6A writers, erasers and readers in cancer	38
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	37
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	37
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	37
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	35
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	35
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	34
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	34
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways	33
Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells	30
Three-dimensional chromatin landscapes in MLLr AML	30
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	30
TCR engineered T cells for solid tumor immunotherapy	30
Correction: Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	29
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma	28
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination	28
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	28
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	27
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response	27
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs	27
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	26
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	26
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	26
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances	26
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells	26
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights	25
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy	25
Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model	25
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review	25
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors	24
The clinical impact of IKZF1 mutation in acute myeloid leukemia	24
Antibody-drug conjugates in breast cancer: current evidence and future directions	24
New exploration of KRASG12D inhibitors and the mechanisms of resistance	23
Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012–2021: a systematic analysis	23
Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance	23
Recent advances and future perspectives in the therapeutics of prostate cancer	22
Whole exome sequencing reveals a novel LRBA mutation and clonal hematopoiesis in a common variable immunodeficiency patient presented with hemophagocytic lymphohistiocytosis	22
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	22
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model	22
A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression	21
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce	21
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	21
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	21
Versatile function of NF-ĸB in inflammation and cancer	21
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity	21
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia	20
Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications	20

Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer	20
Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan	20
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy	20
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma	19
Downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling	19
Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms	19
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	19
Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	18
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study	17
The roles of tissue resident macrophages in health and cancer	17
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	17
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	17
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications	17
A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia	17
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development	16
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	16
Immunotherapy in chronic lymphocytic leukemia: advances and challenges	16
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies	15
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	15
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	15
Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4/PDHA1 signaling and NMDAR-mediated iron export	15
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	14
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	14
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults	14
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis	14
COVID-19 vaccination associated severe immune thrombocytopenia	14
Roles of the intestinal microbiota and microbial metabolites in acute GVHD	14
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	14
Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients	14
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	14
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	14
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma	13
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	13
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer	13
Revealing the role of the gut microbiota in enhancing targeted therapy efficacy for lung adenocarcinoma	13
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	13
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	13
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	13
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer	13
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	13
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	13
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	13
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting	13
Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy	13
CUL4B-DDB1-COP1-mediated UTX downregulation promotes colorectal cancer progression	12
CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway	12
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma	12
TLR7/8 signaling activation enhances the potency of human pluripotent stem cell-derived eosinophils in cancer immunotherapy for solid tumors	12
MMP14 from BM-MSCs facilitates progression and Ara-C resistance in acute myeloid leukemia via the JAK/STAT pathway	12
ZMIZ2 facilitates hepatocellular carcinoma progression via LEF1 mediated activation of Wnt/β-catenin pathway	12
CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy	12
Role of CDK4 as prognostic biomarker in Soft Tissue Sarcoma and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment	12
Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma	12
The role of organoids in cancer research	12
Identification of adenoid subtype characterized with immune-escaped phenotype in lung squamous carcinoma based on transcriptomics	11
Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases	11
Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects	11
RNA binding proteins in MLL-rearranged leukemia	11
Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence	11
AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibition	11
Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting	11
The genomic analysis brings a new piece to the molecular jigsaw of idiopathic erythrocytosis	11
Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells	11
Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a	10
Reconstructed colorectal cancer model to dissect the anti-tumor effect of mesenchymal stromal cells derived extracellular vesicles	10
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era	10
Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets	10
19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway	10
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer	10
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy	10
Heterogeneity of the tumor immune microenvironment and its clinical relevance	10
Trends in platelet count among cancer patients	10
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies	10
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study	10
Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer	10
RHO GTPase family in hepatocellular carcinoma	10
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	9
CD44 promotes hepatocellular carcinoma progression via upregulation of YAP	9
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers	9
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells	9

CAR-T cell combination therapies in hematologic malignancies	9
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials	9
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease	9
Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell inhibition	9
Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma	9
Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting	8
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy	8
LINP1 represses unfolded protein response by directly inhibiting eIF2α phosphorylation to promote cutaneous squamous cell carcinoma	8
ANXA6/TRPV2 axis promotes lymphatic metastasis in head and neck squamous cell carcinoma by inducing autophagy	8
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression	8
Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China	8
GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment	8
Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer	8
The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury	8
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors	8
Identification of a novel NPM1 mutation in acute myeloid leukemia	8
Molecular profiling of skin cells identifies distinct cellular signatures in radiation-induced skin injury across various stages in the murine dataset	8
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer	8
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect	8
Current insight into the regulation of PD-L1 in cancer	8
Secretogranin II influences the assembly and function of MHC class I in melanoma	8
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells	8
Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma	8
Recent advances in Lynch syndrome	8
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses	7
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	7
Current and future therapies for follicular lymphoma	7
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting	7
A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis	7
Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells	7
The clinical landscape of CAR NK cells	7
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers	7
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance	7
Radiation-induced exosomal miR-21 enhances tumor proliferation and invasiveness in breast cancer: implications for poor prognosis in radiotherapy patients	7
p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma	7
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified	7
Epigenetic alterations of TP53INP1 by EHMT2 regulate the cell cycle in gastric cancer	6
Increasing cure rates of solid tumors by immune checkpoint inhibitors	6
Genetic factors, risk prediction and AI application of thrombotic diseases	6
Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor	6
Natural killer cell-based cancer immunotherapy: from basics to clinical trials	6
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	6
Bone marrow sympathetic neuropathy is a hallmark of hematopoietic malignancies and it involves severe ultrastructural damage	6
CD105+CAF-derived exosomes CircAMPK1 promotes pancreatic cancer progression by activating autophagy	6
Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts	6
Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments	6
Targeting metabolic reprogramming in chronic lymphocytic leukemia	6
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion	6
Deciphering tumor-infiltrating dendritic cells in the single-cell era	6
Recent advances and challenges of bispecific antibodies in solid tumors	6
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia	6
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting	6
Targeting CD22 for B-cell hematologic malignancies	6
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment	6
New insight into circRNAs: characterization, strategies, and biomedical applications	6
Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment	5
Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits	5
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling	5
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies	5
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera	5
Targeting the integrated stress response in hematologic malignancies	5
Age-related accumulation of B-1 cell progenitors in mice reflects changes in miR15a/16-1 expression and radioresistance capacity	5
New approaches to idiopathic neutropenia in the era of clonal hematopoiesis	5
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development	5
Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	5
Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis	5
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis	5
Focal adhesion kinase: from biological functions to therapeutic strategies	5
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy	5
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside	5
The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer devel	5
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro	5
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner	5
Chimeric antigen receptor engineered natural killer cells for cancer therapy	5
Sphingosine kinase 1 contributes to the metastatic potential of epithelial ovarian cancer to the adipocyte-rich niche	5